$ICUI
ICU MEDICAL INC/DE Stock $icui

$icui Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000088398417000032 Filed on May 12, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$247.7M	$89.86M
YoY Change	175.71%	10.27%
Cost Of Revenue	$158.8M	$40.62M
YoY Change	290.91%	4.24%
Gross Profit	$88.95M	$49.23M
YoY Change	80.66%	15.8%
Gross Profit Margin	35.9%	54.79%
Selling, General & Admin	$64.89M	$21.98M
YoY Change	195.27%	8.93%
% of Gross Profit	72.95%	44.63%
Research & Development	$11.64M	$3.313M
YoY Change	251.37%	-23.1%
% of Gross Profit	13.09%	6.73%
Depreciation & Amortization	$11.59M	$4.801M
YoY Change	141.49%	3.72%
% of Gross Profit	13.04%	9.75%
Operating Expenses	$105.9M	$25.29M
YoY Change	318.89%	-19.82%
Operating Profit	-$16.98M	$23.95M
YoY Change	-170.93%	118.22%
Interest Expense	$513.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$107.0K	$147.0K
YoY Change	-27.21%	-72.05%
Pretax Income	$45.85M	$24.09M
YoY Change	90.3%	109.51%
Income Tax	-$10.02M	$5.932M
% Of Pretax Income	-21.84%	24.62%
Net Earnings	$55.86M	$18.16M
YoY Change	207.62%	87.49%
Net Earnings / Revenue	22.55%	20.21%
Basic Earnings Per Share	$3.03	$1.13
Diluted Earnings Per Share	$2.86	$1.08
COMMON SHARES
Basic Shares Outstanding	18.44M shares	16.04M shares
Diluted Shares Outstanding	19.55M shares	16.87M shares

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$201.9M	$383.7M
YoY Change	-47.38%	8.15%
Cash & Equivalents	$201.9M	$347.4M
Short-Term Investments		$36.40M
Other Short-Term Assets	$3.727M	$15.50M
YoY Change	-75.95%	10.71%
Inventory	$445.7M	$49.24M
Prepaid Expenses
Receivables	$137.7M	$55.67M
Other Receivables	$12.20M	$11.30M
Total Short-Term Assets	$886.5M	$515.4M
YoY Change	72.0%	13.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$377.8M	$74.64M
YoY Change	406.14%	-9.3%
Goodwill	$6.583M	$6.463M
YoY Change	1.86%	337.28%
Intangibles	$159.1M	$23.48M
YoY Change	577.86%	252.65%
Long-Term Investments
YoY Change
Other Assets	$31.82M	$15.90M
YoY Change	100.14%	60.61%
Total Long-Term Assets	$586.5M	$120.5M
YoY Change	386.62%	20.12%
TOTAL ASSETS
Total Short-Term Assets	$886.5M	$515.4M
Total Long-Term Assets	$586.5M	$120.5M
Total Assets	$1.473B	$636.0M
YoY Change	131.63%	14.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$37.43M	$12.68M
YoY Change	195.21%	1.04%
Accrued Expenses	$121.6M	$21.33M
YoY Change	470.32%	4.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$160.7M	$34.01M
YoY Change	372.5%	3.37%
LONG-TERM LIABILITIES
Long-Term Debt	$75.00M	$0.00
YoY Change
Other Long-Term Liabilities	$89.40M	$2.900M
YoY Change	2982.76%	141.67%
Total Long-Term Liabilities	$164.4M	$2.900M
YoY Change	5568.97%	141.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$160.7M	$34.01M
Total Long-Term Liabilities	$164.4M	$2.900M
Total Liabilities	$331.2M	$40.00M
YoY Change	728.0%	10.5%
SHAREHOLDERS EQUITY
Retained Earnings	$572.8M	$469.8M
YoY Change	21.93%	12.23%
Common Stock	$588.2M	$151.7M
YoY Change	287.71%	26.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$8.933M
YoY Change	-100.0%	1023.65%
Treasury Stock Shares	0.000 shares	101.0K shares
Shareholders Equity	$1.142B	$595.9M
YoY Change
Total Liabilities & Shareholders Equity	$1.473B	$636.0M
YoY Change	131.63%	14.72%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	$55.86M	$18.16M
YoY Change	207.62%	87.49%
Depreciation, Depletion And Amortization	$11.59M	$4.801M
YoY Change	141.49%	3.72%
Cash From Operating Activities	-$76.61M	$17.30M
YoY Change	-542.95%	30.52%
INVESTING ACTIVITIES
Capital Expenditures	$16.40M	$3.963M
YoY Change	313.73%	68.14%
Acquisitions	$157.1M	$0.00
YoY Change
Other Investing Activities	-$157.1M	$4.700M
YoY Change	-3442.55%	-79.2%
Cash From Investing Activities	-$173.9M	$560.0K
YoY Change	-31154.11%	-97.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$3.718M	$16.90M
YoY Change	-78.0%	1077.49%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.600M	-$10.28M
YoY Change	-164.21%	-238.12%
NET CHANGE
Cash From Operating Activities	-$76.61M	$17.30M
Cash From Investing Activities	-$173.9M	$560.0K
Cash From Financing Activities	$6.600M	-$10.28M
Net Change In Cash	-$243.9M	$7.576M
YoY Change	-3319.54%	-81.39%
FREE CASH FLOW
Cash From Operating Activities	-$76.61M	$17.30M
Capital Expenditures	$16.40M	$3.963M
Free Cash Flow	-$93.01M	$13.33M
YoY Change	-797.61%	22.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000883984
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19799799	shares
CY2017Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	ICU MEDICAL INC/DE
CY2016Q4	icui	Accrued Salaries And Benefits AccruedSalariesAndBenefits	5702000	USD
CY2017Q1	icui	Accrued Salaries And Benefits AccruedSalariesAndBenefits	57580000	USD
CY2016Q4	icui	Accrued Value Added Tax AccruedValueAddedTax	1472000	USD
CY2017Q1	icui	Accrued Value Added Tax AccruedValueAddedTax	2120000	USD
CY2016Q1	icui	Bargainpurchasegainnoncashaddback Bargainpurchasegainnoncashaddback	0	USD
CY2017Q1	icui	Bargainpurchasegainnoncashaddback Bargainpurchasegainnoncashaddback	63237000	USD
CY2016Q1	icui	Business Combination Consideration Transferred Equity Issued Fair Value BusinessCombinationConsiderationTransferredEquityIssuedFairValue	0	USD
CY2017Q1	icui	Business Combination Consideration Transferred Equity Issued Fair Value BusinessCombinationConsiderationTransferredEquityIssuedFairValue	413139000	USD
CY2017Q1	icui	Business Combination Consideration Transferred Liabilities Incurred Gross BusinessCombinationConsiderationTransferredLiabilitiesIncurredGross	75000000	USD
CY2017Q1	icui	Contingentconsiderationgross Contingentconsiderationgross	225000000	USD
CY2016Q1	icui	Contractliabilities Contractliabilities	0	USD
CY2017Q1	icui	Contractliabilities Contractliabilities	60792000	USD
CY2017Q1	icui	Discountonequityissuedasconsideration Discountonequityissuedasconsideration	37261000	USD
CY2017Q1	icui	Earnout Target EarnoutTarget	1000000000	USD
CY2016Q1	icui	Estimatedworkingcapitaladjustment Estimatedworkingcapitaladjustment	0	USD
CY2017Q1	icui	Estimatedworkingcapitaladjustment Estimatedworkingcapitaladjustment	7512000	USD
CY2017Q1	icui	Fee Cap First Twelve Months FeeCapFirstTwelveMonths	62500000	USD
CY2017Q1	icui	Fee Cap Sixmonthssubsequenttofirsttwelvemonths FeeCapSixmonthssubsequenttofirsttwelvemonths	31300000	USD
CY2016Q1	icui	Incometaxexcesstaxbenefitadjustment Asu201609 Adoption IncometaxexcesstaxbenefitadjustmentASU201609Adoption	2300000	USD
CY2017Q1	icui	Incometaxexcesstaxbenefitadjustment Asu201609 Adoption IncometaxexcesstaxbenefitadjustmentASU201609Adoption	8300000	USD
CY2016Q1	icui	Increase Decreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes	5145000	USD
CY2017Q1	icui	Increase Decreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes	-10909000	USD
CY2016Q4	icui	Miscellaneousacquisitionrelatedaccrual Miscellaneousacquisitionrelatedaccrual	2750000	USD
CY2017Q1	icui	Miscellaneousacquisitionrelatedaccrual Miscellaneousacquisitionrelatedaccrual	1400000	USD
CY2017Q1	icui	Neb Revenue NEBRevenue	11200000	USD
CY2016Q4	icui	Outsidesalescommissions Outsidesalescommissions	1141000	USD
CY2017Q1	icui	Outsidesalescommissions Outsidesalescommissions	7969000	USD
CY2017Q1	icui	Paymenttoacquirebusinessnetofworkingcapitaladjustments Paymenttoacquirebusinessnetofworkingcapitaladjustments	177527000	USD
CY2016Q4	icui	Prepaidinsuranceandpropertytaxes Prepaidinsuranceandpropertytaxes	1649000	USD
CY2017Q1	icui	Prepaidinsuranceandpropertytaxes Prepaidinsuranceandpropertytaxes	3617000	USD
CY2016Q4	icui	Prepaidothertaxes Prepaidothertaxes	1018000	USD
CY2017Q1	icui	Prepaidothertaxes Prepaidothertaxes	2738000	USD
CY2016Q4	icui	Prepaids Hi Stransaction PrepaidsHIStransaction	0	USD
CY2017Q1	icui	Prepaids Hi Stransaction PrepaidsHIStransaction	19237000	USD
CY2016Q1	icui	Provision For Warranty And Returns ProvisionForWarrantyAndReturns	39000	USD
CY2017Q1	icui	Provision For Warranty And Returns ProvisionForWarrantyAndReturns	1286000	USD
CY2016Q1	icui	Restructuringandstrategictransaction Restructuringandstrategictransaction	0	USD
CY2017Q1	icui	Restructuringandstrategictransaction Restructuringandstrategictransaction	29401000	USD
CY2017Q1	icui	Strategictransactionexpenses Strategictransactionexpenses	21100000	USD
CY2016Q1	icui	Thirdparty Inventory ThirdpartyInventory	0	USD
CY2017Q1	icui	Thirdparty Inventory ThirdpartyInventory	7437000	USD
CY2017Q1	icui	Transitional Service Agreement Setup Costs TransitionalServiceAgreementSetupCosts	22000000	USD
CY2017Q1	icui	Treasury Stock Purchase Plan TreasuryStockPurchasePlan	40000000	USD
CY2017Q1	icui	Treasury Stock Purchase Plan Remaining Available TreasuryStockPurchasePlanRemainingAvailable	7200000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14641000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	37427000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56161000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	137699000	USD
CY2016Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	7912000	USD
CY2017Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5297000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	1107000	USD
CY2017Q1	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	4401000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2017Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1614000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25896000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	121638000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	4177000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	3202000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	158259000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	165641000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21272000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-19243000	USD
CY2017Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P9Y0M
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	162828000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	586212000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1073000	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1096000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3400000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6239	shares
CY2016Q4	us-gaap	Assets Assets	704688000	USD
CY2017Q1	us-gaap	Assets Assets	1473036000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	569097000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	886543000	USD
CY2017Q1	us-gaap	Assets Held For Sale Long Lived Fair Value Disclosure AssetsHeldForSaleLongLivedFairValueDisclosure	2508000	USD
CY2016Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0	USD
CY2017Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	2508000	USD
CY2017Q1	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	3200000	shares
CY2017Q1	us-gaap	Business Acquisition Share Price BusinessAcquisitionSharePrice	140.75
CY2017Q1	us-gaap	Business Combination Acquired Receivables Fair Value BusinessCombinationAcquiredReceivablesFairValue	362000	USD
CY2016Q1	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0	USD
CY2017Q1	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	63237000	USD
CY2017Q1	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	684666000	USD
CY2017Q1	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	450400000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	19000000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	29475000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	4766000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	12381000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	54794000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities Noncurrent BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent	27101000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	5000000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	139000000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	417317000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	775004000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities	68510000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther	31283000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	288486000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	522000	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	437000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	336164000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	347370000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	445082000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201862000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11206000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-243220000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16338000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19798000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16338000	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19798000	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1633000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	1980000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	22259000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	57892000	USD
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	15180000	USD
CY2017Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	33885000	USD
CY2017Q1	us-gaap	Contractual Obligation ContractualObligation	214278000	USD
CY2017Q1	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	42430000	USD
CY2017Q1	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	113369000	USD
CY2017Q1	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	15815000	USD
CY2017Q1	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	22743000	USD
CY2017Q1	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	19921000	USD
CY2016Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	0	USD
CY2017Q1	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	0	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	40622000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	158794000	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0	USD
CY2017Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000	USD
CY2017Q1	us-gaap	Debt Instrument Interest Rate Terms DebtInstrumentInterestRateTerms	Interest on the Senior Note is variable and will accrue at the London Interbank Offered Rate plus (i) 2.25% per year for the first 12 months, and (ii) 2.50% per annum thereafter.
CY2017Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2020-02-03
CY2017Q1	us-gaap	Debt Instrument Restrictive Covenants DebtInstrumentRestrictiveCovenants	The Senior Note has restrictions, beginning on the effective date and thereafter, pertaining to limitations on debt, liens, loans, advances, acquisitions, other investments, dividends, redemptions, repurchases of equity interests, fundamental changes in the line of business, dispositions, transactions with affiliates, dividend and payment restrictions affecting subsidiaries, changes in line of business and accounting changes or change in fiscal year.
CY2016Q4	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	0	USD
CY2017Q1	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	4372000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	21935000	USD
CY2017Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	11196000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1370000	USD
CY2017Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6214000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4801000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11594000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.13
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.03
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.08
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.86
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	3630000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	692000	USD
CY2016Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.22
CY2017Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2016Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	2500000	USD
CY2016Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2017Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	881732000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	24542000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19382000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	74504000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	13894000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	16200000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	16282000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	16421000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	16834000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	46925000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	173517000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22383000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	154135000	USD
CY2016Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	3243000	USD
CY2017Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	3748000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1000	USD
CY2017Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-18000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	5577000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	6583000	USD
CY2016Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2017Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	1015000	USD
CY2017Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-9000	USD
CY2017Q1	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	0	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	49233000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	88945000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	24092000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	45848000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5932000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10015000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1383000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11456000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2552000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	82266000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8014000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	39907000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4866000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22233000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3474000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	66573000	USD
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	828000	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1110000	shares
CY2017Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	5000000	USD
CY2017Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	178517000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22383000	USD
CY2017Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	159135000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	16414000	USD
CY2017Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	282330000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	49264000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	445684000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	28435000	USD
CY2017Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	91405000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4415000	USD
CY2017Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	71949000	USD
CY2016Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	528000	USD
CY2017Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	0	USD
CY2016Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1200000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	704688000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1473036000	USD
CY2016Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2017Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	162786000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40537000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	160679000	USD
CY2017Q1	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	19000000	USD
CY2016Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	1107000	USD
CY2017Q1	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	68832000	USD
CY2016Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	1519000	USD
CY2017Q1	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	1519000	USD
CY2017Q1	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	1300000	USD
CY2017Q1	us-gaap	Long Term Debt LongTermDebt	75000000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	75000000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	96536000	USD
CY2017Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	216304000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10279000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6600000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	560000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-173903000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17295000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76609000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	147000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-406000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	25288000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	105928000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	23945000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16983000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	26547000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	6375000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3212000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	3312000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5515000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	8133000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2319000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15779000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	0	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	517000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1740000	USD
CY2017Q1	us-gaap	Other Assets Current OtherAssetsCurrent	3727000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	31823000	USD
CY2017Q1	us-gaap	Other Commitment OtherCommitment	9015000	USD
CY2017Q1	us-gaap	Other Commitment Due In Fifth Year OtherCommitmentDueInFifthYear	0	USD
CY2017Q1	us-gaap	Other Commitment Due In Fourth Year OtherCommitmentDueInFourthYear	300000	USD
CY2017Q1	us-gaap	Other Commitment Due In Second Year OtherCommitmentDueInSecondYear	3205000	USD
CY2017Q1	us-gaap	Other Commitment Due In Third Year OtherCommitmentDueInThirdYear	3223000	USD
CY2017Q1	us-gaap	Other Commitments Future Minimum Payments Remainder Of Fiscal Year OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear	2287000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4099000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2029000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1159000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	48000	USD
CY2016Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2948000	USD
CY2017Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	6311000	USD
CY2016Q4	us-gaap	Other Receivables OtherReceivables	0	USD
CY2017Q1	us-gaap	Other Receivables OtherReceivables	50964000	USD
CY2016Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	6000	USD
CY2017Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	15951000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	16897000	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3718000	USD
CY2017Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	4666000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3700000	USD
CY2017Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	260000000	USD
CY2016Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2017Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	157097000	USD
CY2016Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	219000	USD
CY2017Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	410000	USD
CY2016Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	7061000	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3963000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16396000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.00
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.00
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7355000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	86594000	USD
CY2016Q4	us-gaap	Prepaid Taxes PrepaidTaxes	11235000	USD
CY2017Q1	us-gaap	Prepaid Taxes PrepaidTaxes	12196000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2017Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1326000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	75000000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11802000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5421000	USD
CY2017Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	12332000	USD
CY2016Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	0	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8992000	USD
CY2016Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1197000	USD
CY2016Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	0	USD
CY2017Q1	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	3122000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	18160000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	55863000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	243955000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	543397000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	85696000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	377756000	USD
CY2016Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2017Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	13000	USD
CY2017Q1	us-gaap	Purchase Obligation PurchaseObligation	103716000	USD
CY2017Q1	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	39218000	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	34757000	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	11259000	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	4477000	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	14005000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3313000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11641000	USD
CY2017Q1	us-gaap	Restructuring Charges RestructuringCharges	8314000	USD
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	1530000	USD
CY2017Q1	us-gaap	Restructuring Reserve RestructuringReserve	5161000	USD
CY2017Q1	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-17000	USD
CY2016Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	423000	USD
CY2017Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	4150000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	516980000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	572843000	USD
CY2016Q1	us-gaap	Revenues Revenues	89855000	USD
CY2017Q1	us-gaap	Revenues Revenues	247739000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	89849000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	231788000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21975000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64886000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3808000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4006000	USD
CY2017Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	25745	shares
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	660155000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1141792000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2017Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	14000	USD
CY2017Q1	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16870000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19549000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16042000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18439000	shares
CY2017Q1	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The amendments in this update remove the second step of the impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The amendments in ASU 2017-04 are effective for the annual or interim impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. This ASU is not expected to have a material impact on our condensed consolidated financial statements or related foot note disclosures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update provide a screen to determine when a set (integrated set of assets and activities) is not a business.  If the screen is not met, it (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace the missing elements. The amendments in ASU 2017-01 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The amendments in this Update should be applied prospectively on or after the effective date. This ASU is not expected to have a material impact on our condensed consolidated financial statements or related foot note disclosures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued No. ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. Current generally accepted accounting principles prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until after the asset has been sold to an outside party. The amendments in ASU 2016-16 eliminates this prohibition, accordingly an entity should recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. Amendments in this update are effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted in the first interim period of an annual reporting period. The amendments should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued No. ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">provides specific guidance on eight cash flow issues where current guidance is unclear or does not include any specifics on classification. The eight specific cash flow issues are: debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with zero coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies, including bank-owned policies; distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle. The amendments in ASU 2016-15 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. Early adoption is permitted. If adopted in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes the interim period. Amendments should be applied using a retrospective transition method to each period presented. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued No. ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update amends the FASB's guidance on the impairment of financial instruments by requiring timelier recording of credit losses on loans and other financial instruments. The ASU adds an impairment model that is based on expected losses rather than incurred losses. The ASU also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted as of the fiscal years beginning after December 15, 2018. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued No. ASU 2016-02, Leases (Topic 842). The amendments in this update require an entity to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement and presentation of expenses will depend on classification as finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued No. ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments. This amendment requires all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in the consolidation of the investee). The amendments in this update will be effective for fiscal years beginning after December 15, 2017. Early adoption of the amendments is not permitted with the exception of the provision requiring the recognition in other comprehensive income the fair value change from instrument-specific credit risk measured using the fair value option for financial instruments. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">        </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU 2014-09.  On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. Subsequent to the issuance of this ASU, the FASB issued three amendments: ASU No. 2016-08 which clarifies principal versus agent considerations; ASU 2016-10 which clarifies guidance related to identifying performance obligations and licensing implementation; and ASU 2016-12 which provides narrow-scope improvements and practical expedients. All of the amendments have the same effective dates mentioned above. We previously disclosed that we did not anticipate a material impact on our consolidated financial statements from adoption of any of the above. We will reassess these ASUs with consideration to their impact on Hospira Infusion Systems ("HIS"). We expect to adopt the full retrospective transition method when adopting this ASU.</font></div></div>

Files In Submission

Name	View Source	Status
0000883984-17-000032-index-headers.html	Edgar Link	pending
0000883984-17-000032-index.html	Edgar Link	pending
0000883984-17-000032.txt	Edgar Link	pending
0000883984-17-000032-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
icui-20170331.xml	Edgar Link	completed
icui-20170331.xsd	Edgar Link	pending
icui-20170331_cal.xml	Edgar Link	unprocessable
icui-20170331_def.xml	Edgar Link	unprocessable
icui-20170331_lab.xml	Edgar Link	unprocessable
icui-20170331_pre.xml	Edgar Link	unprocessable
icui-ex311_20170331x10q.htm	Edgar Link	pending
icui-ex312_x20170331x10q.htm	Edgar Link	pending
icui-ex321_x20170331x10q.htm	Edgar Link	pending
icui0331201710-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICUI
ICU MEDICAL INC/DE Stock $icui

2017 Q1 Form 10-Q Financial Statement

#000088398417000032 Filed on May 12, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICUI ICU MEDICAL INC/DE Stock $icui

2017 Q1 Form 10-Q Financial Statement

#000088398417000032 Filed on May 12, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICUI
ICU MEDICAL INC/DE Stock $icui